[go: up one dir, main page]

MX2017012342A - Compuestos biciclicos fusionados para el tratamiento de enfermedades,. - Google Patents

Compuestos biciclicos fusionados para el tratamiento de enfermedades,.

Info

Publication number
MX2017012342A
MX2017012342A MX2017012342A MX2017012342A MX2017012342A MX 2017012342 A MX2017012342 A MX 2017012342A MX 2017012342 A MX2017012342 A MX 2017012342A MX 2017012342 A MX2017012342 A MX 2017012342A MX 2017012342 A MX2017012342 A MX 2017012342A
Authority
MX
Mexico
Prior art keywords
diseases
treatment
fusioned
bicycle compounds
compounds
Prior art date
Application number
MX2017012342A
Other languages
English (en)
Other versions
MX370897B (es
Inventor
Mohan Raju
Anthony Pratt Benjamin
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of MX2017012342A publication Critical patent/MX2017012342A/es
Publication of MX370897B publication Critical patent/MX370897B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos bicíclicos fusionados, composiciones y método para uso para el tratamiento de enfermedades.
MX2017012342A 2015-03-26 2016-03-25 Compuestos bicíclicos fusionados para el tratamiento de enfermedades, MX370897B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562138725P 2015-03-26 2015-03-26
PCT/IB2016/000606 WO2016151403A1 (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Publications (2)

Publication Number Publication Date
MX2017012342A true MX2017012342A (es) 2018-06-11
MX370897B MX370897B (es) 2020-01-09

Family

ID=56072361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012342A MX370897B (es) 2015-03-26 2016-03-25 Compuestos bicíclicos fusionados para el tratamiento de enfermedades,

Country Status (16)

Country Link
US (4) US10421759B2 (es)
EP (2) EP3715348A1 (es)
JP (1) JP6843061B2 (es)
KR (1) KR20180003545A (es)
CN (1) CN107912042A (es)
AU (2) AU2016238523A1 (es)
BR (1) BR112017020374A2 (es)
CA (1) CA2980394A1 (es)
CL (1) CL2017002405A1 (es)
CO (1) CO2017010621A2 (es)
HK (1) HK1249756A1 (es)
IL (1) IL254572A0 (es)
MX (1) MX370897B (es)
RU (2) RU2017137366A (es)
SG (2) SG10201908881PA (es)
WO (1) WO2016151403A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016151403A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
SG10202011665SA (en) * 2016-05-25 2020-12-30 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
WO2017205684A1 (en) * 2016-05-25 2017-11-30 Akarna Therapeutics, Ltd. Combination therapies with farnesoid x receptor (fxr) modulators
TW201910332A (zh) * 2017-06-02 2019-03-16 英商艾卡那治療有限公司 稠合的雙環化合物
CN108264474B (zh) * 2018-02-09 2019-10-25 浙江师范大学 一种色胺及其衍生物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
EP1648408A4 (en) * 2003-07-23 2006-11-29 Exelixis Inc AZEPINE DERIVATIVES AS PHARMACEUTICAL AGENTS
BRPI0514269A (pt) 2004-08-10 2008-06-10 Exelixis Inc compostos heterocìclicos como agentes farmacêuticos
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US20090203577A1 (en) * 2005-12-15 2009-08-13 Exelixis, Inc. Azepinoindole Derivatives As Pharmaceutical Agents
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090131409A1 (en) 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
MY192927A (en) * 2014-11-21 2022-09-15 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
EP3237419B1 (en) * 2014-12-22 2021-02-17 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
WO2016151403A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease

Also Published As

Publication number Publication date
BR112017020374A2 (pt) 2018-06-05
RU2021107054A (ru) 2021-03-31
US20200079782A1 (en) 2020-03-12
RU2017137366A3 (es) 2019-07-17
US10421759B2 (en) 2019-09-24
SG10201908881PA (en) 2019-11-28
CO2017010621A2 (es) 2018-01-31
CL2017002405A1 (es) 2018-04-27
CA2980394A1 (en) 2016-09-29
JP6843061B2 (ja) 2021-03-17
JP2018510876A (ja) 2018-04-19
WO2016151403A1 (en) 2016-09-29
EP3274350A1 (en) 2018-01-31
US20210214362A1 (en) 2021-07-15
SG11201707610PA (en) 2017-10-30
MX370897B (es) 2020-01-09
IL254572A0 (en) 2017-11-30
HK1249756A1 (zh) 2018-11-09
KR20180003545A (ko) 2018-01-09
AU2016238523A1 (en) 2017-11-09
US20180118752A1 (en) 2018-05-03
RU2017137366A (ru) 2019-04-26
CN107912042A (zh) 2018-04-13
US20230002394A1 (en) 2023-01-05
AU2020256301A1 (en) 2020-11-05
EP3715348A1 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
UY37018A (es) Inhibidores bicíclicos de pad4
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
GT201700188A (es) Anticuerpos contra tau y sus usos
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.
MX369857B (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
CL2017002304A1 (es) Métodos para tratar enfermedades
MX389099B (es) Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
MA41174A (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MX382659B (es) Proceso para la preparación de derivados de tiazol.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
EA201691203A1 (ru) Твёрдые формы тенофовира
MX380240B (es) Preparación de piperidin-4-carbotioamida.

Legal Events

Date Code Title Description
FG Grant or registration